
  
    
      
        
        Gaucher_NNP disease_NN is_VBZ the_DT most_RBS common_JJ lysosomal_NN storage_NN disorder_NN (_( Box_NNP 1_LS )_) ._. A_DT deficiency_NN of_IN
        the_DT enzyme_NN glucocerebrosidase_NN (_( Figure_NN 1_LS )_) causes_NNS accumulation_NN of_IN the_DT glycolipid_NN
        glucocerebroside_NN in_IN macrophages_NNS throughout_IN the_DT body_NN ._. In_IN the_DT viscera_NN ,_, glucocerebroside_NN
        arises_VBZ mainly_RB from_IN the_DT biodegradation_NN of_IN red_JJ and_CC white_JJ blood_NN cells_NNS ._. In_IN the_DT brain_NN ,_,
        glucocerebroside_NN arises_VBZ from_IN the_DT turnover_NN of_IN complex_JJ lipids_NNS during_IN brain_NN development_NN and_CC
        the_DT formation_NN of_IN the_DT myelin_NN sheath_NN of_IN nerves_NNS ._. The_DT disease_NN may_MD be_VB discovered_VBN as_IN an_DT
        incidental_JJ finding_NN in_IN the_DT elderly_JJ because_IN of_IN mild_JJ thrombocytopenia_NN or_CC splenomegaly_RB ,_, or_CC it_PRP
        may_MD present_VB early_RB in_IN life_NN with_IN hepatosplenomegaly_RB ,_, thrombocytopenia_NN ,_, anemia_NN ,_, and_CC bone_NN
        lesions_NNS ._.
        Until_IN 1990_CD ,_, treatment_NN consisted_VBD only_RB of_IN palliative_JJ measures_NNS such_JJ as_IN splenectomy_NN and_CC hip_NN
        replacement_NN ._. The_DT development_NN of_IN enzyme_NN replacement_NN therapy_NN for_IN Gaucher_NNP disease_NN ,_, that_WDT is_VBZ ,_,
        exogenous_JJ administration_NN of_IN the_DT missing_VBG enzyme_NN ,_, is_VBZ a_DT triumph_NN of_IN translational_NN medicine_NN ._. At_IN
        the_DT same_JJ time_NN ,_, powerful_JJ commercial_JJ interests_NNS may_MD have_VB been_VBN influential_JJ in_IN physicians_NNS
        adopting_VBG a_DT high-dose_JJ rather_RB than_IN a_DT low-dose_JJ treatment_NN schedule_NN ._. Moreover_RB ,_, the_DT high_JJ cost_NN of_IN
        enzyme_NN replacement_NN therapy_NN forces_NNS us_PRP to_TO consider_VB what_WP society_NN can_MD afford_VB in_IN the_DT way_NN of_IN
        palliative_JJ treatments_NNS for_IN very_RB rare_JJ diseases_NNS ._.
      
      
        The_DT History_NN of_IN Enzyme_NNP Replacement_NNP Therapy_NNP
        The_DT possibility_NN that_IN the_DT therapeutic_JJ replacement_NN of_IN enzymes_NNS missing_VBG from_IN lysosomes_NNS could_MD
        be_VB achieved_VBN was_VBD first_RB raised_VBN by_IN de_IN Duve_NNP forty_NN years_NNS ago_RB when_WRB he_PRP wrote_VBD :_: “ Any_DT substance_NN that_WDT
        is_VBZ taken_VBN up_RP intracellularly_RB by_IN an_DT endocytic_JJ process_NN is_VBZ likely_JJ to_TO end_VB up_RP within_IN lysosomes_NNS ._.
        This_DT obviously_RB opens_VBZ up_RP many_JJ possibilities_NNS for_IN interaction_NN ,_, including_VBG replacement_NN therapy_NN”
        [_NN 1_CD ]_NN ._.
        Type_NNP 1_CD Gaucher_NNP disease_NN ,_, the_DT most_RBS common_JJ type_NN ,_, seems_VBZ a_DT particularly_RB suitable_JJ target_NN for_IN
        enzyme_NN replacement_NN therapy_NN because_IN of_IN the_DT lack_NN of_IN central_JJ nervous_JJ system_NN involvement_NN
        (_( visceral_NN damage_NN in_IN Gaucher_NNP disease_NN is_VBZ reversible_JJ whereas_IN the_DT brain_NN damage_NN usually_RB is_VBZ not_RB )_) ._.
        By_IN the_DT 1970_CD s_VBZ ,_, the_DT underlying_VBG enzyme_NN deficiency_NN had_VBD been_VBN identified_VBN ,_, and_CC methods_NNS had_VBD been_VBN
        developed_VBN to_TO purify_NN the_DT enzyme_NN from_IN human_JJ placenta_NN in_IN a_DT high_JJ state_NN of_IN purity_NN ._. Three_CD groups_NNS
        of_IN investigators_NNS then_RB attempted_VBD to_TO treat_VB the_DT disease_NN by_IN infusing_VBG exogenous_JJ enzyme_NN ._.
        In_IN the_DT United_NNP States_NNPS ,_, at_IN the_DT National_NNP Institutes_NNPS of_IN Health_NNP in_IN Bethesda_NNP ,_, Maryland_NNP ,_, the_DT
        unaltered_JJ enzyme_NN was_VBD infused_VBN directly_RB into_IN the_DT venous_JJ circulation_NN [_NN 2_CD ]_NN ;_: at_IN City_NNP of_IN Hope_NNP in_IN
        Duarte_NNP ,_, California_NNP ,_, it_PRP was_VBD entrapped_JJ in_IN red_JJ cell_NN membranes_NNS coated_VBN with_IN antibody_NN in_IN an_DT
        effort_NN to_TO direct_VB it_PRP to_TO macrophages_NNS [_NN 3_CD ]_NN ._. In_IN Harrow_NNP ,_, United_NNP Kingdom_NNP ,_, the_DT enzyme_NN was_VBD delivered_VBN
        entrapped_JJ in_IN liposomes_NNS [_NN 4_CD ]_NN ._. Although_IN some_DT mildly_RB encouraging_VBG results_NNS were_VBD achieved_VBN ,_, it_PRP was_VBD
        clear_JJ that_DT none_NN of_IN these_DT approaches_NNS was_VBD likely_JJ to_TO be_VB translated_VBN into_IN a_DT useful_JJ
        treatment_NN ._.
        The_DT needed_VBN conceptual_JJ breakthrough_NN was_VBD provided_VBN by_IN the_DT identification_NN of_IN a_DT mannose_NN
        receptor_NN on_IN macrophages_NNS and_CC the_DT suggestion_NN that_IN this_DT might_MD prove_VB useful_JJ in_IN replacement_NN
        therapy_NN for_IN Gaucher_NNP disease_NN [_NN 5_CD ]_NN ._. This_DT led_VBN to_TO the_DT development_NN of_IN a_DT modified_VBN enzyme_NN ,_,
        processed_VBN to_TO expose_VB mannose_NN ,_, and_CC to_TO its_PRP$ production_NN on_IN an_DT industrial_JJ scale_NN from_IN placentas_NNS ._.
        After_IN the_DT gene_NN encoding_VBG the_DT enzyme_NN was_VBD cloned_VBN [_NN 6_CD ]_NN ,_, a_DT recombinant_JJ product_NN became_VBD
        available_JJ ._.
      
      
        The_DT Pivotal_NNP Study_NNP
        The_DT first_JJ study_NN of_IN commercially_RB produced_VBN mannose-enriched_JJ glucocerebrosidase_NN was_VBD carried_VBN
        out_IN in_IN Bethesda_NNP ,_, Maryland_NNP ,_, on_IN only_RB 12_CD patients_NNS ,_, presumably_RB because_IN of_IN a_DT limited_JJ supply_NN of_IN
        the_DT enzyme_NN [_NN 7_CD ]_NN ._. Given_VBN this_DT small_JJ cohort_NN of_IN patients_NNS ,_, only_RB a_DT single_JJ dose_NN (_( 60_CD units_NNS /_NN kg_NN )_) was_VBD
        administered_VBN ._. This_DT dose_NN was_VBD given_VBN every_DT two_CD weeks_NNS to_TO ten_CD of_IN the_DT patients_NNS ,_, while_IN two_CD
        patients_NNS received_VBD it_PRP weekly_JJ ._. This_DT is_VBZ manifestly_RB an_DT unusual_JJ dose_NN schedule_NN for_IN a_DT preparation_NN
        with_IN a_DT circulating_VBG half-life_NN of_IN only_RB about_IN 12_CD min_NN that_WDT is_VBZ being_VBG targeted_VBN to_TO a_DT relatively_RB
        small_JJ number_NN of_IN receptors_NNS ._. Many_JJ of_IN the_DT patients_NNS studied_VBN did_VBD not_RB live_VB near_IN Bethesda_NNP ,_, and_CC it_PRP
        is_VBZ likely_JJ that_IN the_DT dose_NN schedule_NN that_WDT was_VBD chosen_VBN was_VBD based_VBN on_IN convenience_NN rather_RB than_IN on_IN
        sound_NN pharmacokinetic_JJ principles_NNS ._. Since_IN it_PRP was_VBD unlikely_JJ that_IN a_DT second_JJ study_NN would_MD be_VB
        launched_VBN if_IN the_DT first_JJ failed_VBD ,_, the_DT investigators_NNS wisely_RB used_VBD a_DT very_RB generous_JJ dose_NN of_IN enzyme_NN
        to_TO maximize_VB the_DT probability_NN that_IN the_DT trial_NN would_MD be_VB successful_JJ ._. Intravenous_NNP administration_NN
        of_IN the_DT enzyme_NN produced_VBD objective_NN clinical_JJ improvement_NN (_( such_JJ as_IN reduced_VBN liver_NN and_CC spleen_NN
        size_NN and_CC increased_VBN hemoglobin_NN levels_NNS and_CC platelet_NN counts_VBZ )_) ._.
        The_DT enzyme_NN was_VBD promptly_RB approved_VBN and_CC marketed_VBN ._. Since_IN only_RB a_DT single_JJ dose_NN had_VBD been_VBN tested_VBN ,_,
        this_DT was_VBD the_DT dose_NN that_IN most_JJS physicians_NNS administered_VBN in_IN clinical_JJ practice_NN ._. But_CC the_DT
        preparation_NN was_VBD extremely_RB costly—about_NN US_NNP $_$ 4_CD ._. 00_CD per_IN unit_NN ._. At_IN the_DT dose_NN used_VBN in_IN the_DT pivotal_JJ
        trial_NN ,_, a_DT 70_CD -_: kg_NN patient_NN would_MD receive_VB enzyme_NN costing_VBG US_NNP $_$ 16_CD ,_, 800_CD every_DT two_CD weeks_NNS ._.
      
      
        Dosage_NNP Considerations_NNP
        
          Visceral_NNP organ_NN responses_NNS ._.
          But_CC was_VBD the_DT large_JJ dose_NN given_VBN actually_RB the_DT dose_NN required_VBN ?_. There_EX were_VBD no_DT data_NNS ,_, and_CC many_JJ
          physicians_NNS were_VBD unwilling_JJ to_TO give_VB less_JJR than_IN the_DT dose_NN that_WDT had_VBD been_VBN used_VBN in_IN the_DT pivotal_JJ
          trial_NN ._. Moreover_RB ,_, since_IN most_JJS physicians_NNS took_VBD care_NN of_IN only_RB one_CD or_CC at_IN most_JJS two_CD patients_NNS with_IN
          the_DT disease_NN ,_, they_PRP were_VBD not_RB in_IN a_DT position_NN to_TO perform_VB a_DT dose-ranging_JJ study_NN ._. And_CC industry_NN
          had_VBD no_DT interest_NN in_IN supporting_VBG studies_NNS to_TO show_VB that_IN a_DT lower_JJR dose_NN yielded_VBD equivalent_NN
          results_NNS ._.
          But_CC clinical_JJ trials_NNS carried_VBD out_IN in_IN our_PRP$ National_NNP Institutes_NNPS of_IN Health–sponsored_NNP General_NNP
          Clinical_NNP Research_NNP Center_NNP quickly_RB established_VBD that_IN a_DT quarter_NN of_IN the_DT dose_NN given_VBN at_IN more_RBR
          frequent_JJ intervals_NNS was_VBD fully_RB effective_JJ [_NN 8_CD ]_NN ._. By_IN 2000_CD ,_, a_DT considerable_JJ body_NN of_IN data_NNS had_VBD
          accumulated_VBN ,_, making_VBG it_PRP possible_JJ to_TO perform_VB meta-analyses_JJ of_IN the_DT relationship_NN between_IN the_DT
          total_JJ monthly_JJ dose_NN ,_, the_DT interval_NN at_IN which_WDT the_DT dose_NN is_VBZ administered_VBN ,_, and_CC the_DT decrease_NN in_IN
          the_DT size_NN of_IN the_DT liver_NN ._. The_DT results_NNS were_VBD clear_JJ (_( Figure_NN 2_LS )_) [_NN 9_CD ]_NN ._. Even_RB a_DT dose_NN of_IN only_RB 15_CD
          units_NNS /_NN kg_NN /_NN mo_NN ,_, one-ninth_JJ of_IN the_DT dose_NN given_VBN in_IN the_DT pivotal_JJ trial_NN ,_, resulted_VBD in_IN an_DT excellent_JJ
          clinical_JJ response_NN ._. Most_JJS patients_NNS were_VBD receiving_VBG a_DT substantial_JJ overdose_NN of_IN an_DT extremely_RB
          costly_JJ preparation_NN ._. The_DT data_NNS indicate_VBP that_IN when_WRB very_RB large_JJ doses_NNS are_VBP administered_VBN ,_, the_DT
          two-week_JJ time_NN interval_NN is_VBZ adequate_JJ to_TO give_VB an_DT optimal_NN response_NN ,_, but_CC when_WRB more_RBR modest_JJ
          doses_NNS are_VBP administered_VBN ,_, more_RBR frequent_JJ infusions_NNS greatly_RB improve_VBP the_DT response_NN [_NN 9_CD ]_NN ._.
          Recent_JJ “ consensus_NN recommendations_NNS ,_,” which_WDT were_VBD supported_VBN in_IN part_NN by_IN the_DT Genzyme_NNP
          Corporation_NNP ,_, the_DT manufacturers_NNS of_IN recombinant_JJ human_JJ glucocerebrosidase_NN (_( imiglucerase_NN ,_,
          brand_NN name_NN Cerezyme_NNP )_) ,_, suggest_VBP that_IN children_NNS be_VB given_VBN an_DT initial_JJ dose_NN of_IN 30_CD to_TO 60_CD units_NNS
          every_DT two_CD weeks_NNS [_NN 10_CD ]_NN ._. But_CC there_EX is_VBZ no_DT high-quality_JJ evidence_NN that_IN such_JJ a_DT costly_JJ treatment_NN
          regimen_NN provides_VBZ results_NNS superior_JJ to_TO those_DT achieved_VBN with_IN smaller_JJR doses_NNS ._. The_DT only_JJ support_NN
          for_IN recommending_VBG this_DT high_JJ dosage_NN comes_VBZ from_IN uncontrolled_JJ studies_NNS showing_VBG that_IN in_IN some_DT
          children_NNS bone_NN lesions_NNS may_MD progress_VB at_IN low_JJ dosages_NNS ._. However_RB ,_, we_PRP know_VBP from_IN our_PRP$ own_JJ
          published_VBN observations_NNS that_WDT skeletal_NN progression_NN and_CC even_RB fractures_NNS also_RB occur_VBP in_IN some_DT
          individuals_NNS receiving_VBG high-dose_JJ therapy_NN [_NN 11_CD ]_NN ._. Thus_RB ,_, I_PRP would_MD caution_VB against_IN any_DT
          recommendations_NNS to_TO give_VB high-dose_JJ therapy_NN that_WDT have_VBP not_RB been_VBN based_VBN on_IN well-designed_JJ
          randomized_JJ ,_, controlled_VBN trials_NNS ._. Having_VBG said_VBN this_DT ,_, I_PRP recognize_VBP that_IN most_JJS ,_, but_CC not_RB all_DT ,_, of_IN
          the_DT patients_NNS that_WDT were_VBD included_VBN in_IN our_PRP$ meta-analyses_JJ were_VBD adults_NNS ,_, whereas_IN the_DT
          company-sponsored_JJ consensus_NN recommendations_NNS refer_VBP to_TO children_NNS ._. However_RB ,_, in_IN the_DT absence_NN of_IN
          any_DT evidence-based_JJ rationale_NN for_IN administering_VBG large_JJ ,_, costly_JJ doses_NNS of_IN enzyme_NN ,_, I_PRP believe_VBP
          that_IN the_DT use_NN of_IN smaller_JJR ,_, more_RBR frequent_JJ doses_NNS is_VBZ the_DT most_RBS prudent_JJ treatment_NN approach_NN ._.
          It_PRP is_VBZ often_RB assumed_VBN that_IN patients_NNS with_IN severe_JJ disease_NN require_VB larger_JJR doses_NNS of_IN enzyme_NN
          than_IN those_DT with_IN mild_JJ disease_NN ,_, but_CC a_DT meta-analysis_JJ based_VBN on_IN liver_NN size_NN or_CC spleen_NN size_NN made_VBD
          it_PRP clear_JJ that_IN this_DT is_VBZ not_RB the_DT case_NN (_( Figure_NN 3_LS )_) [_NN 12_CD ]_NN ._. Large_JJ organs_NNS shrink_VB more_RBR rapidly_RB than_IN
          smaller_JJR ones_NNS ,_, and_CC this_DT is_VBZ true_JJ regardless_RB of_IN the_DT dose_NN that_WDT is_VBZ used_VBN [_NN 13_CD ]_NN ._.
        
        
          Skeletal_NNP response_NN ._.
          The_DT response_NN of_IN enlarged_JJ viscera_NN to_TO enzyme_NN infusion_NN is_VBZ much_RB more_RBR rapid_JJ than_IN the_DT
          response_NN of_IN bones_NNS ._. In_IN one_CD early_JJ study_NN ,_, the_DT large_JJ dose_NN used_VBN in_IN the_DT pivotal_JJ trial_NN was_VBD given_VBN
          for_IN up_IN to_TO four_CD years_NNS to_TO patients_NNS with_IN bone_NN disease_NN ,_, and_CC although_IN the_DT response_NN was_VBD slow_JJ ,_,
          gradual_JJ improvement_NN occurred_VBD [_NN 14_CD ]_NN ._. Strangely_NNP ,_, the_DT authors_NNS concluded_VBD that_IN large_JJ doses_NNS were_VBD
          required—_NN“ strangely_RB ,_,” because_IN they_PRP did_VBD not_RB give_VB smaller_JJR doses_NNS to_TO any_DT patient_NN ._.
          Subsequently_RB ,_, it_PRP was_VBD shown_VBN that_IN less_JJR than_IN a_DT quarter_NN of_IN the_DT dose_NN (_( only_RB 30_CD units_NNS /_NN kg_NN /_NN mo_NN )_)
          produced_VBD an_DT equivalent_NN response_NN [_NN 15_CD ]_NN ._.
        
      
      
        Whom_NNP to_TO Treat_NNP
        The_DT severity_NN of_IN Gaucher_NNP disease_NN is_VBZ very_RB variable_JJ ._. We_PRP have_VBP estimated_VBN that_IN some_DT 60_CD %_NN of_IN
        patients_NNS homozygous_JJ for_IN the_DT common_JJ 
        c_SYM ._. 1226_CD C_NNP →_NN G_NNP (_( N_NNP 370_CD S_NNP )_) mutation_NN never_RB come_VB to_TO medical_JJ attention_NN [_NN 16_CD ]_NN ._.
        Accordingly_RB ,_, many—possibly_RB most—patients_NNS with_IN Gaucher_NNP disease_NN require_VBP no_DT treatment_NN ._. In_IN
        adults_NNS ,_, the_DT disease_NN is_VBZ rarely_RB progressive_JJ [_NN 11_CD ,_, 17_CD ]_NN ._. What_WP you_PRP see_VBP is_VBZ what_WP you_PRP have_VBP ,_, more_JJR or_CC
        less_JJR ._. Bone_NNP fractures_NNS ,_, of_IN course_NN ,_, are_VBP not_RB gradual_JJ events_NNS but_CC sudden_JJ ones_NNS ._. But_CC almost_RB
        invariably_RB they_PRP occur_VBP in_IN patients_NNS who_WP already_RB have_VBP very_RB substantial_JJ ,_, demonstrable_JJ bone_NN
        disease_NN ._. In_IN children_NNS ,_, the_DT situation_NN is_VBZ different_JJ ,_, and_CC progression_NN is_VBZ common_JJ ._. It_PRP is_VBZ only_RB
        with_IN proper_JJ awareness_NN of_IN the_DT natural_JJ history_NN of_IN the_DT disease_NN that_IN one_PRP can_MD make_VB rational_JJ
        judgments_NNS regarding_VBG who_WP needs_VBZ treatment_NN ._.
      
      
        Individualized_NNP Treatment_NNP
        Evaluating_VBG dose–response_NN relationships_NNS in_IN patients_NNS with_IN Gaucher_NNP disease_NN has_VBZ been_VBN
        difficult_JJ for_IN several_JJ reasons_NNS ._. The_DT number_NN of_IN new_JJ patients_NNS requiring_VBG therapy_NN is_VBZ relatively_RB
        small_JJ ,_, and_CC the_DT Genzyme_NNP Corporation_NNP has_VBZ done_VBN little_JJ to_TO encourage_VB the_DT performance_NN of_IN
        dose–response_NN studies_NNS ,_, making_VBG it_PRP difficult_JJ to_TO enroll_VB patients_NNS ._. But_CC beyond_IN that_DT ,_, the_DT
        response_NN of_IN patients_NNS to_TO any_DT dose_NN is_VBZ variable_JJ ._. Some_DT authors_NNS have_VBP suggested_VBN that_IN this_DT may_MD be_VB
        due_JJ to_TO individual_JJ differences_NNS in_IN dose_NN requirements—that_NN some_DT patients_NNS are_VBP relatively_RB
        resistant_JJ and_CC require_VB a_DT large_JJ dose_NN ,_, while_IN others_NNS do_VBP well_RB on_IN a_DT small_JJ dose_NN [_NN 18_CD ]_NN ._. This_DT is_VBZ an_DT
        attractive_JJ concept_NN ,_, but_CC is_VBZ it_PRP correct_JJ ?_. Another_DT meta-analysis_JJ indicates_VBZ that_IN it_PRP is_VBZ not_RB ._.
        Rather_RB ,_, there_EX are_VBP patients_NNS who_WP respond_VBP poorly_RB to_TO any_DT dose_NN and_CC others_NNS who_WP respond_VBP well_RB to_TO
        any_DT dose_NN [_NN 19_CD ]_NN ._. Moreover_RB ,_, quadrupling_VBG the_DT dose_NN does_VBZ not_RB increase_VB the_DT rate_NN of_IN response_NN
        [_NN 11_CD ]_NN ._.
      
      
        What_WP Does_VBZ the_DT Future_NNP Hold_VB ?_.
        The_DT quality_NN of_IN life_NN for_IN patients_NNS with_IN Gaucher_NNP disease_NN has_VBZ been_VBN greatly_RB improved_VBN by_IN the_DT
        development_NN of_IN enzyme_NN replacement_NN therapy_NN ._. Manufacturing_NNP and_CC selling_VBG the_DT enzyme_NN has_VBZ also_RB
        been_VBN enormously_RB profitable_JJ for_IN industry_NN ._. This_DT profitability_NN has_VBZ served_VBN as_IN a_DT stimulus_NN for_IN
        the_DT development_NN of_IN enzyme_NN replacement_NN treatments_NNS for_IN diseases_NNS less_RBR common_JJ and_CC generally_RB
        less_RBR responsive_JJ to_TO treatment_NN than_IN Gaucher_NNP disease_NN ._. Given_VBN the_DT small_JJ target_NN population_NN ,_, these_DT
        treatments_NNS are_VBP enormously_RB costly_JJ on_IN a_DT per-patient_JJ basis_NN ._. Treatments_NNP for_IN Fabry_NNP disease_NN and_CC
        Hurler-_NNP Scheie_NNP disease_NN (_( also_RB called_VBN mucopolysaccharidosis_NNS I_PRP )_) are_VBP already_RB licensed_VBN ,_, and_CC
        others_NNS are_VBP on_IN the_DT way_NN [_NN 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._. This_DT brings_VBZ us_PRP face-to-face_JJ with_IN a_DT major_JJ ethical_JJ dilemma_NN ._.
        We_PRP do_VBP not_RB put_VB a_DT price_NN on_IN human_JJ life_NN ._. Yet_RB health-care_NN resources_NNS are_VBP a_DT zero-sum_JJ game_NN ._. What_WP is_VBZ
        spent_VBN on_IN one_CD disease_NN cannot_NN be_VB spent_VBN on_IN another_DT ._. Is_VBZ it_PRP better_JJR to_TO treat_VB one_CD child_NN with_IN
        Hurler-_NNP Scheie_NNP disease_NN [_NN 22_CD ]_NN or_CC to_TO provide_VB good_JJ prenatal_NN care_NN to_TO 100_CD women_NNS who_WP might_MD not_RB
        otherwise_RB obtain_VB it_PRP ,_, or_CC for_IN that_DT matter_NN ,_, to_TO feed_VB 1_CD ,_, 000_CD malnourished_JJ children_NNS ?_. These_DT are_VBP
        difficult_JJ decisions_NNS that_WDT will_MD be_VB forced_VBN on_IN us_PRP as_IN enzyme_NN replacement_NN and_CC other_JJ
        high-technology_NN therapies_NNS come_VBP of_IN age_NN ._.
      
    
  
